The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.
Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.
The FDA has granted Fast Track designation to 2 of Pfizer and BioNTech’s vaccine candidates against COVID-19.
A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.
Dayvigo (lemborexant; Eisai) is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
